BiotechTube

Methylprednisolone + Prednisolone

ApprovedTerminated
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Immune Reconstitution Inflammatory Syndrome

Conditions

Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal

Trial Timeline

Sep 1, 2010 → Feb 1, 2012

NCT ID
NCT01211665

About Methylprednisolone + Prednisolone

Methylprednisolone + Prednisolone is a approved stage product being developed by Biogen for Immune Reconstitution Inflammatory Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT01211665. Target conditions include Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal.

What happened to similar drugs?

6 of 20 similar drugs in Immune Reconstitution Inflammatory Syndrome were approved

Approved (6) Terminated (1) Active (14)
✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
✅IgPro10CSLApproved
✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved
✅Flebogamma 5% DIFGrifolsApproved
✅Asceniv™ADMA BiologicsApproved
✅BivigamADMA BiologicsApproved
🔄SatralizumabChugai PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01211665ApprovedTerminated

Competing Products

20 competing products in Immune Reconstitution Inflammatory Syndrome

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
SatralizumabChugai PharmaceuticalPhase 3
47
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
RomiplostimKyowa KirinPhase 1/2
32
AMG 531Kyowa KirinPhase 2/3
38
Romiplostim + PlaceboKyowa KirinPhase 3
40
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Romiplostim and danazolKyowa KirinPhase 2
31
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
29
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
29
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
40
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
29
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
35
HerombopagJiangsu Hengrui MedicinePhase 3
36
Zostavax®MerckPre-clinical
18
Raltegravir + AtazanavirMerckPre-clinical
26
ZostavaxMerckPre-clinical
26
MK-8723 + Matching PlaceboMerckPhase 1
29